Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOWER: Blinatumomab vs Standard Chemotherapy in Relapsed/Refractory B-precursor ALL
2013-000536-10Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2013
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Blinatumomab with Standard-of-care chemotherapy (2 arms). Primary endpoint: Overall survival. Started Sep 2013; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2013-000536-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000536-10.